IPP Bureau

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

By IPP Bureau - February 09, 2026

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

By IPP Bureau - February 09, 2026

HCG clinicians contributing to one of the largest bodies of oncology research from India

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

By IPP Bureau - February 09, 2026

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

By IPP Bureau - February 09, 2026

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

By IPP Bureau - February 09, 2026

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

By IPP Bureau - February 09, 2026

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Wanbury reports explosive Q3 profit surge, signals strong growth ahead
Wanbury reports explosive Q3 profit surge, signals strong growth ahead

By IPP Bureau - February 09, 2026

Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year

KIMS Hospitals crosses Rs. 1,000 crore quarterly revenue milestone
KIMS Hospitals crosses Rs. 1,000 crore quarterly revenue milestone

By IPP Bureau - February 09, 2026

MHRA warns of extremely rare vision risk linked to semaglutide
MHRA warns of extremely rare vision risk linked to semaglutide

By IPP Bureau - February 09, 2026

Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

By IPP Bureau - February 07, 2026

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

By IPP Bureau - February 07, 2026

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

By IPP Bureau - February 07, 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

By IPP Bureau - February 07, 2026

Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

By IPP Bureau - February 07, 2026

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

By IPP Bureau - February 07, 2026

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers

Latest Stories

Interviews

Packaging